WALTHAM, MA -- April 18, 2007 -- Offering a break-through advance in performance, productivity, and cost efficiency, PerkinElmer, Inc. (NYSE: PKI), a global leader in Health Sciences and Photonics, has launched its powerful new 1536 Head LumiLux™ Cellular Screening Platform for high-throughput screening (HTS) and ultra high-throughput screening (uHTS) kinetic flash and glow luminescent cellular assays.

With advanced liquid handling automation for walk-away capability, the 1536 LumiLux Cellular Screening Platform is the only dedicated flash luminescence instrument which enables simultaneous 1536 “inject and read” flash luminescence assays, allowing laboratories to produce over 100,000 data points per day.

Flash luminescence platforms are increasingly utilized by pharmaceutical companies and researchers over traditional fluorescent technologies for primary and secondary screening of drug targets. According to recent market research, fifty percent of HTS labs are expected to switch from the traditional kinetic fluorescence assays to flash luminescence technologies in the next two to three years.

“Flash luminescence provides a highly-sensitive tool for assaying the very important GPCR target class without the artifacts or false positives normally associated with fluorescent detection, providing more physiologically relevant data,” said Mary Duseau, business leader, Detection and Analysis Systems, Molecular Medicine Business Element for PerkinElmer Life and Analytical Sciences. “The 1536 miniaturized format and ‘inject and read’ automation capability significantly ramps up the throughput to meet the rigorous performance requirements of the most demanding labs, dramatically increasing productivity and improving cost-efficiencies.”

In addition to its top-performing high-throughput screening capabilities, the 1536 LumiLux Screening Platform also has a cell stirrer feature that allows it to work with suspension cells for uHTS screens. The 1536 LumiLux head accessory is fully field-upgradeable, or available as part of a complete screening system.

"The 1536 tip Lumilux Screening Platform will allow Kalypsys to significantly increase the throughput of flash luminescent GPCR screens. Increased throughput reduces the time it takes to complete a screen and often results in greater consistency when comparing data across a large number of plates", said Rob Bukar, associate director of screening, Kalypsys, Inc, an innovative clinical stage pharmaceutical company which recently adopted the LumiLux platform for its ultra high-throughput screening labs. "Since the new LumiLux-1536 was designed to be optimized for the low volume requirements of 1536 well assays, we expect improved well-to-well variance across the plate and greater accuracy in our results."

LumiLux Cellular Screening Platform complements PerkinElmer’s comprehensive drug discovery instrumentation and reagents portfolio, further demonstrating the company’s commitment to innovation in HTS and uHTS technologies in the cellular sciences. LumiLux is compatible with standard luminescence reagents technologies, but has been optimized for PerkinElmer’s recently-acquired AequoScreen™ luminescent reagent technology for GPCR analysis.

For more product information on the 1536 LumiLux Screening Platform or other PerkinElmer drug discovery and research technologies, visit PerkinElmer online at las.perkinelmer.com or contact your sales representative.

The integration of the 1536 head from Nanoscreen LLC onto the LumiLux Cellular Screening Platform was developed in collaboration with Nanoscreen LLC.

Factors Affecting Future Performance
This press release contains “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to estimates and projections of future earnings per share and revenue growth and other financial results, developments relating to our customers and end-markets, and plans concerning business development opportunities. Words such as “believes,” “intends,” “anticipates,” “plans,” “expects,” “projects,” “forecasts,” “will” and similar expressions, and references to guidance, are intended to identify forward-looking statements. Such statements are based on management’s current assumptions and expectations and no assurances can be given that our assumptions or expectations will prove to be correct. A number of important risk factors could cause actual results to differ materially from the results described, implied or projected in any forward-looking statements. These factors include, without limitation: (1) our failure to introduce new products in a timely manner; (2) our ability to execute acquisitions and license technologies, or to successfully integrate acquired businesses and licensed technologies into our existing business or to make them profitable; (3) our failure to protect adequately our intellectual property; (4) the loss of any of our licenses or licensed rights; (5) our ability to compete effectively; (6) fluctuation in our quarterly operating results and our ability to adjust our operations to address unexpected changes; (7) our ability to produce an adequate quantity of products to meet our customers’ demands; (8) our failure to maintain compliance with applicable government regulations; (9) regulatory changes; (10) economic, political and other risks associated with foreign operations; (11) our ability to retain key personnel; (12) restrictions in our credit agreement; (13) our ability to realize the full value of our intangible assets; and (14) other factors which we describe under the caption “Risk Factors” in our most recent annual report on Form 10-K and in our most recent quarterly report on Form 10-Q and in our other filings with the Securities and Exchange Commission. We disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.

Other Information
Health Sciences end markets include genetic screening, environmental, service, biopharma, and medical imaging. Photonics markets include sensors and specialty lighting.